REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Find a specialty pharmacy

List of specialty pharmacies.

REVLIMID is only available through a select network of specialty pharmacies due to a restricted distribution program called Lenalidomide REMS.1 These specialty pharmacies help to manage the handling and shipping of REVLIMID and may provide additional resources.